Interestingly, a phase II randomized study targeting IL-13 was not successful in patients with IPF (125), suggesting that Th2-mediated immunity might not be the sole contributor in the development of fibrotic responses in patients with IPF. This evidence concerns the gene IL13 and idiopathic pulmonary fibrosis.